Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 10/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MDH1 | P40925 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxirane SCHEMBL26699073 | 0.95 | SHBG (0.81) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| Formaldehyde SCHEMBL290371 | 0.91 | SHBG (0.88) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| Formaldehyde SCHEMBL28440479 | 0.89 | SHBG (0.84) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| Formaldehyde SCHEMBL28351070 | 0.86 | SHBG (0.78) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| Ethylene SCHEMBL8593493 | 0.85 | SHBG (0.91) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| SCHEMBL31282065 | 0.85 | SHBG (1.00) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| SCHEMBL10141 | 0.85 | SHBG (1.00) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| Phenol SCHEMBL11364645 | 0.84 | SHBG (0.75) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| SCHEMBL10785821 | 0.83 | SHBG (0.95) | SHBGESR1ESR2CYP3A4SMN1; SMN2 | |
| SCHEMBL22773183 | 0.83 | SHBG (0.95) | SHBGESR1ESR2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661853-A1 | LIPID NANOPARTICLES FOR THE TREATMENT OF OCULAR DISEASES | Universitat de Barcelona (ES) | 2025-12-17 | — | — | EP | claimed |
| CN-111360226-B | Super exhaust block used in large-scale die casting die | 菲斯达精密工业部件（苏州）有限公司 | 2025-05-09 | — | — | CN | claimed |
| WO-2024165565-A1 | LIPID NANOPARTICLES FOR THE TREATMENT OF OCULAR DISEASES | UNIVERSITAT DE BARCELONA (ES) | 2024-08-15 | — | — | WO | claimed |
| EP-4410281-A1 | LIPID NANOPARTICLES FOR THE TREATMENT OF OCULAR DISEASES | Universitat de Barcelona (ES) | 2024-08-07 | — | — | EP | claimed |
| CN-115637104-B | Preparation method and application of ethyl orthosilicate-siloxane-surfactant hybrid material | 山东大学 | 2023-12-22 | — | — | CN | claimed |
| CN-116389118-A | Superset secondary login-free method based on Keycloak | 北谷电子股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-112641894-B | A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction | 北京中医药大学 | 2022-06-17 | — | — | CN | claimed |
| WO-2022082324-A1 | SOLID-LIQUID EXTRACTION PROCESS FOR RECOVERING IONS OF INTEREST FROM SOLID MATERIALS | PONTIFICIA UNIVERSIDAD CATÓLICA (CL) | 2022-04-28 | — | — | WO | claimed |
| EP-3571216-B1 | APOC-II MIMETIC PEPTIDES | US HEALTH (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12599556-B2 | Ophthalmic compositions | BIOTHERAVISION INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4717257-A1 | COMPOSITION FOR THE TREATMENT OF DRY EYE | Omnivision GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2004100886-A2 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040086896-A1 | Polynucleotides and polypeptides associated with the NF-kB pathway | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | disclosed |
| WO-2004022114-A1 | METHODS OF INHIBITING THE ADHERENCE OF CONTACT LENSES TO THEIR PACKAGING | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| EP-1379540-A2 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY | Bristol-Myers Squibb Company (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030224486-A1 | Polynucleotides and polypeptides associated with the NF-kB pathway | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2002086076-A2 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599556-B2 | Ophthalmic compositions | HSD11B2, TSLP, HSD3B1 | SHBG 437/4885ESR1 3701/4885ESR2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.